Related Experiment Video
Updated: May 1, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
6.9K
Serotonin transporter polymorphic region 5-HTTLPR modulates risk for Parkinson's disease
Xiong Zhang1, Xing Cheng1, Yan-Bing Hu1
1Department of Geriatrics & Neurology, The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Neurobiology of Aging
|April 2, 2014
Summary
The serotonin transporter gene (SLC6A4) 5-HTTLPR polymorphism is linked to increased Parkinson's disease risk. Specific SLC6A4 genotypes, impacting 5-HTT expression, were associated with Parkinson's disease in a Chinese cohort.
Area of Science:
- Neurogenetics
- Molecular Psychiatry
- Human Genetics
Background:
- The role of serotonin transporter gene (SLC6A4) polymorphisms in Parkinson's disease (PD) requires further clarification.
- Investigating genetic associations with PD is crucial for understanding disease etiology.
Purpose of the Study:
- To examine the relationship between SLC6A4 polymorphisms (5-HTTLPR and rs25531) and Parkinson's disease in a Chinese population.
- To identify novel variants within the SLC6A4 gene and their potential link to PD.
Main Methods:
- Genotyping of SLC6A4 polymorphisms (5-HTTLPR and rs25531) in 504 PD patients and 504 controls.
- Haplotype and genotype analysis to identify associations with PD.
- Sub-classification of genotypes based on their impact on 5-HTT expression.
Main Results:
- The 5-HTTLPR polymorphism showed a significant association with an increased risk of Parkinson's disease (p=0.005).
- The rs25531 polymorphism alone was not significantly associated with PD susceptibility.
- A lower prevalence of the high 5-HTT expressing LALA genotype was observed in PD patients, suggesting a differential expression pattern.
Conclusions:
- SLC6A4 polymorphisms, particularly 5-HTTLPR, are associated with Parkinson's disease etiology.
- The serotonergic system, influenced by SLC6A4 variants, may play a role in PD pathogenesis.
- Novel SLC6A4 variants, including 20G, were identified in the studied population.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K